Robert Lanza Insider Trading $ACTC Ocata Therapeutics, Inc.
FREE EMAIL WATCHDOG
Get free email notifications about insider trading for Robert Lanza.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of Robert Lanza. Robert Lanza is Chief Scientfic Officer in Ocata Therapeutics, Inc. ($ACTC) and Chief Scientific Officer in Ocata Therapeutics, Inc. ($ACTC).
Robert Lanza in Ocata Therapeutics, Inc.
Industry: PHARMACEUTICAL PREPARATIONS [2834]
Position of Robert Lanza: Chief Scientfic Officer, Chief Scientific Officer
Holdings: 28,529,003 shares
Latest Transaction: Jul 26 2012
Last 4 weeks trend: HOLD
Last 3 months trend: HOLD
Latest Insider Trading Transactions of Robert Lanza in Ocata Therapeutics, Inc.
| 1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
|---|---|---|---|---|---|---|---|
| No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Page: 1
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Jul 26 2012 | ACTC | Ocata Therapeutics ... | Lanza Robert | Chief Scientific Of ... | Grant | A | 0.00 | 1,285,714 | 0 | 28,529,003 | 27.2 M to 28.5 M (+4.72 %) |
| Jul 26 2012 | ACTC | Ocata Therapeutics ... | Lanza Robert | Chief Scientific Of ... | Grant | A | 0.00 | 1,285,714 | 0 | 27,243,289 | 26 M to 27.2 M (+4.95 %) |
| Jan 25 2012 | ACTC | Ocata Therapeutics ... | Lanza Robert | Chief Scientific Of ... | Sell | S | 0.19 | 6,658,300 | 1,277,728 | 25,957,575 | 32.6 M to 26 M (-20.41 %) |
| Jan 25 2012 | ACTC | Ocata Therapeutics ... | Lanza Robert | Chief Scientific Of ... | Sell | S | 0.18 | 1,000,000 | 175,400 | 32,615,875 | 33.6 M to 32.6 M (-2.97 %) |
| Sep 30 2011 | ACTC | Ocata Therapeutics ... | Lanza Robert | Chief Scientific Of ... | Sell | S | 0.15 | 608,225 | 93,058 | 33,615,875 | 34.2 M to 33.6 M (-1.78 %) |
| Sep 30 2011 | ACTC | Ocata Therapeutics ... | Lanza Robert | Chief Scientific Of ... | Sell | S | 0.15 | 108,080 | 16,320 | 34,224,100 | 34.3 M to 34.2 M (-0.31 %) |
| Sep 30 2011 | ACTC | Ocata Therapeutics ... | Lanza Robert | Chief Scientific Of ... | Sell | S | 0.15 | 10,000 | 1,520 | 34,332,180 | 34.3 M to 34.3 M (-0.03 %) |
| Aug 18 2011 | ACTC | Ocata Therapeutics ... | Lanza Robert | Chief Scientific Of ... | Option Exercise | A | 0.16 | 15,000,000 | 2,356,500 | 15,000,000 | |
| Aug 18 2011 | ACTC | Ocata Therapeutics ... | Lanza Robert | Chief Scientific Of ... | Grant | A | 0.00 | 15,000,000 | 0 | 34,342,180 | 19.3 M to 34.3 M (+77.55 %) |
| Jun 30 2011 | ACTC | Ocata Therapeutics ... | Lanza Robert | Chief Scientific Of ... | Option Exercise | M | 0.05 | 750,000 | 37,500 | 0 | |
| Jun 30 2011 | ACTC | Ocata Therapeutics ... | Lanza Robert | Chief Scientific Of ... | Buy | M | 0.05 | 750,000 | 37,500 | 19,342,180 | 18.6 M to 19.3 M (+4.03 %) |
| Dec 08 2010 | ACTC | Ocata Therapeutics ... | Lanza Robert | Chief Scientific Of ... | Sell | S | 0.15 | 728,136 | 106,745 | 18,492,180 | 19.2 M to 18.5 M (-3.79 %) |
| Dec 08 2010 | ACTC | Ocata Therapeutics ... | Lanza Robert | Chief Scientific Of ... | Sell | S | 0.13 | 1,271,864 | 171,320 | 19,220,316 | 20.5 M to 19.2 M (-6.21 %) |
| Dec 01 2010 | ACTC | Ocata Therapeutics ... | Lanza Robert | Chief Scientific Of ... | Sell | S | 0.10 | 3,800,000 | 382,660 | 20,492,180 | 24.3 M to 20.5 M (-15.64 %) |
| Dec 01 2010 | ACTC | Ocata Therapeutics ... | Lanza Robert | Chief Scientific Of ... | Sell | S | 0.08 | 204,000 | 16,810 | 24,292,180 | 24.5 M to 24.3 M (-0.83 %) |
| Dec 01 2010 | ACTC | Ocata Therapeutics ... | Lanza Robert | Chief Scientific Of ... | Sell | S | 0.08 | 5,000 | 405 | 24,496,180 | 24.5 M to 24.5 M (-0.02 %) |
| Dec 01 2010 | ACTC | Ocata Therapeutics ... | Lanza Robert | Chief Scientific Of ... | Sell | S | 0.08 | 385,340 | 32,060 | 24,501,180 | 24.9 M to 24.5 M (-1.55 %) |
| Dec 01 2010 | ACTC | Ocata Therapeutics ... | Lanza Robert | Chief Scientific Of ... | Sell | S | 0.08 | 405,660 | 33,954 | 24,886,520 | 25.3 M to 24.9 M (-1.60 %) |
| Nov 24 2010 | ACTC | Ocata Therapeutics ... | Lanza Robert | Chief Scientific Of ... | Sell | S | 0.07 | 115,000 | 8,050 | 25,292,180 | 25.4 M to 25.3 M (-0.45 %) |
| Nov 24 2010 | ACTC | Ocata Therapeutics ... | Lanza Robert | Chief Scientific Of ... | Sell | S | 0.07 | 17,000 | 1,207 | 25,407,180 | 25.4 M to 25.4 M (-0.07 %) |
| Nov 24 2010 | ACTC | Ocata Therapeutics ... | Lanza Robert | Chief Scientific Of ... | Sell | S | 0.07 | 118,000 | 8,496 | 25,424,180 | 25.5 M to 25.4 M (-0.46 %) |
| Nov 24 2010 | ACTC | Ocata Therapeutics ... | Lanza Robert | Chief Scientific Of ... | Sell | S | 0.07 | 4,900 | 363 | 25,542,180 | 25.5 M to 25.5 M (-0.02 %) |
| Nov 24 2010 | ACTC | Ocata Therapeutics ... | Lanza Robert | Chief Scientific Of ... | Sell | S | 0.08 | 75,000 | 5,625 | 25,547,080 | 25.6 M to 25.5 M (-0.29 %) |
| Nov 24 2010 | ACTC | Ocata Therapeutics ... | Lanza Robert | Chief Scientific Of ... | Sell | S | 0.08 | 105,000 | 7,980 | 25,622,080 | 25.7 M to 25.6 M (-0.41 %) |
| Nov 24 2010 | ACTC | Ocata Therapeutics ... | Lanza Robert | Chief Scientific Of ... | Sell | S | 0.08 | 5,100 | 393 | 25,727,080 | 25.7 M to 25.7 M (-0.02 %) |
| Nov 24 2010 | ACTC | Ocata Therapeutics ... | Lanza Robert | Chief Scientific Of ... | Sell | S | 0.08 | 10,000 | 775 | 25,732,180 | 25.7 M to 25.7 M (-0.04 %) |
| Nov 24 2010 | ACTC | Ocata Therapeutics ... | Lanza Robert | Chief Scientific Of ... | Sell | S | 0.08 | 10,000 | 798 | 25,742,180 | 25.8 M to 25.7 M (-0.04 %) |
| Nov 24 2010 | ACTC | Ocata Therapeutics ... | Lanza Robert | Chief Scientific Of ... | Sell | S | 0.08 | 215,250 | 17,220 | 25,752,180 | 26 M to 25.8 M (-0.83 %) |
| Nov 24 2010 | ACTC | Ocata Therapeutics ... | Lanza Robert | Chief Scientific Of ... | Sell | S | 0.08 | 3,750 | 302 | 25,967,430 | 26 M to 26 M (-0.01 %) |
| Nov 24 2010 | ACTC | Ocata Therapeutics ... | Lanza Robert | Chief Scientific Of ... | Sell | S | 0.07 | 292,000 | 21,082 | 25,971,180 | 26.3 M to 26 M (-1.11 %) |
| Nov 24 2010 | ACTC | Ocata Therapeutics ... | Lanza Robert | Chief Scientific Of ... | Sell | S | 0.07 | 440,000 | 30,492 | 26,263,180 | 26.7 M to 26.3 M (-1.65 %) |
| Nov 24 2010 | ACTC | Ocata Therapeutics ... | Lanza Robert | Chief Scientific Of ... | Sell | S | 0.07 | 45,000 | 3,132 | 26,703,180 | 26.7 M to 26.7 M (-0.17 %) |
| Nov 24 2010 | ACTC | Ocata Therapeutics ... | Lanza Robert | Chief Scientific Of ... | Sell | S | 0.08 | 5,000 | 415 | 26,748,180 | 26.8 M to 26.7 M (-0.02 %) |
| Sep 22 2010 | ACTC | Ocata Therapeutics ... | Lanza Robert | Chief Scientific Of ... | Sell | S | 0.07 | 36,506 | 2,464 | 26,753,180 | 26.8 M to 26.8 M (-0.14 %) |
| Sep 22 2010 | ACTC | Ocata Therapeutics ... | Lanza Robert | Chief Scientific Of ... | Sell | S | 0.07 | 5,000 | 340 | 26,789,686 | 26.8 M to 26.8 M (-0.02 %) |
| Sep 22 2010 | ACTC | Ocata Therapeutics ... | Lanza Robert | Chief Scientific Of ... | Sell | S | 0.07 | 260,794 | 17,734 | 26,794,686 | 27.1 M to 26.8 M (-0.96 %) |
| Sep 22 2010 | ACTC | Ocata Therapeutics ... | Lanza Robert | Chief Scientific Of ... | Sell | S | 0.07 | 47,500 | 3,235 | 27,055,480 | 27.1 M to 27.1 M (-0.18 %) |
| Sep 22 2010 | ACTC | Ocata Therapeutics ... | Lanza Robert | Chief Scientific Of ... | Sell | S | 0.07 | 18,000 | 1,228 | 27,102,980 | 27.1 M to 27.1 M (-0.07 %) |
| Sep 22 2010 | ACTC | Ocata Therapeutics ... | Lanza Robert | Chief Scientific Of ... | Sell | S | 0.07 | 188,200 | 12,892 | 27,120,980 | 27.3 M to 27.1 M (-0.69 %) |
| Sep 22 2010 | ACTC | Ocata Therapeutics ... | Lanza Robert | Chief Scientific Of ... | Sell | S | 0.07 | 19,000 | 1,303 | 27,309,180 | 27.3 M to 27.3 M (-0.07 %) |
| Sep 22 2010 | ACTC | Ocata Therapeutics ... | Lanza Robert | Chief Scientific Of ... | Sell | S | 0.07 | 15,000 | 1,035 | 27,328,180 | 27.3 M to 27.3 M (-0.05 %) |
| Sep 22 2010 | ACTC | Ocata Therapeutics ... | Lanza Robert | Chief Scientific Of ... | Sell | S | 0.07 | 10,000 | 695 | 27,343,180 | 27.4 M to 27.3 M (-0.04 %) |
| Aug 23 2010 | ACTC | Ocata Therapeutics ... | Lanza Robert | Chief Scientfic Off ... | Sell | S | 0.08 | 258,519 | 19,389 | 27,353,180 | 27.6 M to 27.4 M (-0.94 %) |
| Aug 23 2010 | ACTC | Ocata Therapeutics ... | Lanza Robert | Chief Scientfic Off ... | Sell | S | 0.08 | 29,600 | 2,223 | 27,611,699 | 27.6 M to 27.6 M (-0.11 %) |
| Aug 23 2010 | ACTC | Ocata Therapeutics ... | Lanza Robert | Chief Scientfic Off ... | Sell | S | 0.08 | 25,000 | 1,880 | 27,641,299 | 27.7 M to 27.6 M (-0.09 %) |
| Aug 23 2010 | ACTC | Ocata Therapeutics ... | Lanza Robert | Chief Scientfic Off ... | Sell | S | 0.08 | 196,181 | 14,812 | 27,666,299 | 27.9 M to 27.7 M (-0.70 %) |
| Aug 23 2010 | ACTC | Ocata Therapeutics ... | Lanza Robert | Chief Scientfic Off ... | Sell | S | 0.08 | 90,700 | 6,893 | 27,862,480 | 28 M to 27.9 M (-0.32 %) |
| Jul 22 2010 | ACTC | Ocata Therapeutics ... | Lanza Robert | Chief Scientific Of ... | Buy | S | 0.07 | 102,850 | 7,200 | 27,953,180 | 27.9 M to 28 M (+0.37 %) |
| Jul 22 2010 | ACTC | Ocata Therapeutics ... | Lanza Robert | Chief Scientific Of ... | Sell | S | 0.07 | 160,300 | 11,221 | 28,056,030 | 28.2 M to 28.1 M (-0.57 %) |
| Jul 22 2010 | ACTC | Ocata Therapeutics ... | Lanza Robert | Chief Scientific Of ... | Sell | S | 0.07 | 17,000 | 1,192 | 28,216,330 | 28.2 M to 28.2 M (-0.06 %) |
| Jul 22 2010 | ACTC | Ocata Therapeutics ... | Lanza Robert | Chief Scientific Of ... | Sell | S | 0.07 | 5,000 | 351 | 28,233,300 | 28.2 M to 28.2 M (-0.02 %) |
| Jul 22 2010 | ACTC | Ocata Therapeutics ... | Lanza Robert | Chief Scientific Of ... | Sell | S | 0.07 | 34,700 | 2,439 | 28,238,330 | 28.3 M to 28.2 M (-0.12 %) |
| Jul 22 2010 | ACTC | Ocata Therapeutics ... | Lanza Robert | Chief Scientific Of ... | Sell | S | 0.07 | 18,900 | 1,332 | 28,273,030 | 28.3 M to 28.3 M (-0.07 %) |
| Jul 22 2010 | ACTC | Ocata Therapeutics ... | Lanza Robert | Chief Scientific Of ... | Sell | S | 0.07 | 255,700 | 18,155 | 28,291,930 | 28.5 M to 28.3 M (-0.90 %) |
| Jul 22 2010 | ACTC | Ocata Therapeutics ... | Lanza Robert | Chief Scientific Of ... | Sell | S | 0.07 | 5,550 | 400 | 28,547,630 | 28.6 M to 28.5 M (-0.02 %) |
| Jun 23 2010 | ACTC | Ocata Therapeutics ... | Lanza Robert | Chief Scientific Of ... | Sell | S | 0.10 | 50,000 | 4,775 | 28,553,180 | 28.6 M to 28.6 M (-0.17 %) |
| Jun 23 2010 | ACTC | Ocata Therapeutics ... | Lanza Robert | Chief Scientific Of ... | Sell | S | 0.10 | 16,000 | 1,534 | 28,603,180 | 28.6 M to 28.6 M (-0.06 %) |
| Jun 23 2010 | ACTC | Ocata Therapeutics ... | Lanza Robert | Chief Scientific Of ... | Sell | S | 0.10 | 93,450 | 8,971 | 28,619,180 | 28.7 M to 28.6 M (-0.33 %) |
| Jun 23 2010 | ACTC | Ocata Therapeutics ... | Lanza Robert | Chief Scientific Of ... | Sell | S | 0.10 | 93,500 | 9,023 | 28,712,630 | 28.8 M to 28.7 M (-0.32 %) |
| Jun 23 2010 | ACTC | Ocata Therapeutics ... | Lanza Robert | Chief Scientific Of ... | Sell | S | 0.10 | 211,000 | 20,467 | 28,806,130 | 29 M to 28.8 M (-0.73 %) |
| Jun 23 2010 | ACTC | Ocata Therapeutics ... | Lanza Robert | Chief Scientific Of ... | Sell | S | 0.10 | 88,050 | 8,585 | 29,017,130 | 29.1 M to 29 M (-0.30 %) |
| Jun 23 2010 | ACTC | Ocata Therapeutics ... | Lanza Robert | Chief Scientific Of ... | Sell | S | 0.10 | 48,000 | 4,704 | 29,105,180 | 29.2 M to 29.1 M (-0.16 %) |
Page: 1